UCI MIND Director named one of OC’s top influential people

Related posts:

1. FDA Advisory Panel Votes in Favor of Full Approval for Lecanemab On June 9, The US Food and Drug Administration convened members of the updated Peripheral and Central Nervous System Drugs Advisory Committee to review the available data for lecanemab, the monoclonal antibody treatment for early Alzheimer’s disease developed by Eisai and Biogen. The members voted unanimously, 6-0, in favor of approval....
2. Dr. Head quoted in Alzforum about cerebrovascular disease in Down syndrome UCI MIND faculty member and professor of pathology, Elizabeth Head, PhD, is quoted in last week’s Alzforum article about Alzheimer’s disease immunotherapies and the high rates of cerebrovascular pathology in people with Down syndrome.   To read the story, visit Alzforum from August 25th....